VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

Overview

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

Full Title of Study: “VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of neovascular age-related macular degeneration – Visual acuity better than 20/400 – Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months – Follow-up period of at least six months Exclusion Criteria:

  • Choroidal neovascularization secondary to any other cause than age-related macular degeneration – Eyes with polypoidal choroidal vasculopathy – Eyes previously submitted to posterior vitrectomy – Other diseases that could affect visual acuity

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institute of Vision, Brasil
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.